Πέμπτη, 11 Απριλίου 2019

Clinical Trials


FDA Approves Expanded Monotherapy Label for Merck's KEYTRUDA® (pembrolizumab)
KENILWORTH, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;--FDA Approves Expanded Monotherapy Label for Merck's KEYTRUDA® (pembrolizumab)
Business Wire Health: Clinical Trials News
00:45
Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases
NEW YORK--(BUSINESS WIRE)--Ophthotech announced today that the Company has converted its option and entered into an exclusive global license agreement with UPenn.
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 23:05
QIAGEN's QuantiFERON®-TB Passes Milestone of 60 Million Tests in Global Fight against Tuberculosis, Current Annual Run Rate Exceeds 12 Million Tests
HILDEN, Germany & GERMANTOWN, Md. & AMSTERDAM--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24QGEN&src=ctag" target="_blank"gt;$QGENlt;/agt;--QIAGEN's QuantiFERON®-TB passes milestone of 60 million tests in global fight against tuberculosis, current annual run rate exceeds 12 million tests
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 23:02
QIAGENs QuantiFERON®-TB erreicht Meilenstein von 60 Millionen Tests im weltweiten Kampf gegen Tuberkulose – aktuelle jährliche Rate liegt bei mehr als 12 Millionen Tests
HILDEN, Deutschland & GERMANTOWN, Md. & AMSTERDAM, Niederlande--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass sein QuantiFERON®-TB-Test, der moderne Goldstandard zur Erkennung latenter Tuberkulose-Infektionen (TB), mehr als 60 Millionen Mal durchgeführt wurde und damit das Leben von Millionen von Patienten weltweit verbessert und wesentlich zum globalen Kampf gegen TB beigetragen hat. QIAGEN entwickelt für den Test QuantiFERON®-TB Gold Plus...
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 23:02
QIAGEN and NeuMoDx expand assay menu for their next generation of fully integrated PCR systems for clinical laboratories in Europe and also announce availability of NeuMoDx 96 version
HILDEN, Germany & ANN ARBOR, Mich.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24QGEN&src=ctag" target="_blank"gt;$QGENlt;/agt;--QIAGEN and NeuMoDx expand assay menu for their next generation of fully integrated PCR systems for clinical laboratories in Europe and also announce a
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 23:01
QIAGEN und NeuMoDx erweitern das Testmenü der nächsten Generation voll integrierten PCR-Systemen für klinische Labore in Europa und kündigen die Verfügbarkeit einer neuen Version von NeuMoDx 96 an
HILDEN, Deutschland & ANN ARBOR, Mich.--(BUSINESS WIRE)--QIAGEN and NeuMoDx expand assay menu for their next generation of fully integrated PCR systems for clinical laboratories in Europe and also announce a
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 23:01
QIAGEN stellt Profil des neuen Meningitis-/Enzephalitis-Panels für QIAstat-Dx zur Erkennung der häufigsten Pathogene im zentralen Nervensystem vor
HILDEN, Deutschland & AMSTERDAM--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) stellte heute neue Daten zum Meningitis-/Enzephalitis-Panel für QIAstat-Dx vor. Das Panel befindet sich in der Endphase der Entwicklung und soll im zweiten Halbjahr 2019 die CE-IVD-Kennzeichnung für den Einsatz auf dem syndromischen Multiplex-Testsystem QIAstat-Dx erhalten. Die ersten Daten belegen die effektive Erkennung der am häufigsten auftretenden Pathogene im zentralen Nervensystem...
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 23:00
QIAGEN Highlights Profile of New QIAstat-Dx Meningitis / Encephalitis pAnel Focused on Most Prevalent Central Nervous System Pathogens
HILDEN, Germany & AMSTERDAM--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24QGEN&src=ctag" target="_blank"gt;$QGENlt;/agt;--QIAGEN highlights profile of new QIAstat-Dx Meningitis / Encephalitis panel focused on most prevalent central nervous system pathogens
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 23:00
ResMed présente AirFit P30i, son premier masque CPAP d'oreillers nasaux doté d'une connexion au sommet de la tête
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE : RMD, ASX : RMD) a présenté aujourd'hui son deuxième masque CPAP doté d'une connexion au sommet de la tête pour le traitement de l'apnée du sommeil, une nouvelle option d'oreiller nasaux, AirFit P30i. La connexion « à tube par le haut » du masque, également présente sur le masque nasal AirFit N30i de ResMed sorti en janvier, maintient le tube à l'écart de l'utilisateur de telle sorte qu'il peut bouger et dormir dans n'importe quelle position. L'AirFit P
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 21:17
Characterization and treatment of congenital thrombotic thrombocytopenic purpura
Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare thrombomicroangiopathy caused by an inherited deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). There are limited data on genotype-phenotype correlation; there is no consensus on treatment. We reviewed the largest cohort of cTTP cases, diagnosed in the United Kingdom, over the past 15 years. Seventy-three cases of cTTP were diagnosed, confirmed by genetic analysis. Ninety-three...
Blood CLINICAL TRIALS AND OBSERVATIONS
Thu Apr 11, 2019 19:00
ResMed stellt AirFit P30i vor, die erste CPAP-Maske mit Nasenkissen und Kopfanschluss
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) stellte heute seine zweite CPAP-Maske mit Kopfanschluss zur Behandlung von Schlafapnoe mit einer neuen Option für Nasenkissen, die AirFit P30i, vor. Der „Tube-up"-Anschluss (Kopfanschluss) der Maske, der ebenfalls bei der im Januar veröffentlichten Nasenmaske AirFit N30i von ResMed zum Einsatz kommt, hält die Schläuche aus dem Weg, sodass der Träger sich in jeder Position bewegen und schlafen kann. AirFit P30i passt 90 Prozent der Träger
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 19:55
ResMed apresenta AirFit P30i, sua primeira máscara CPAP com almofadas nasais conectadas à região superior da cabeça
SAN DIEGO--(BUSINESS WIRE)--Hoje a ResMed (NYSE: RMD, ASX: RMD) apresentou sua segunda máscara CPAP conectada à região superior da cabeça para o tratamento de apneia do sono, uma nova opção de máscara nasal: AirFit P30i. A conexão para cima do tubo da máscara, também apresentada na máscara nasal AirFit N30i da ResMed lançada em janeiro, posicionou o tubo de forma que os usuários possam se movimentar e dormir em qualquer posição. A AirFit P30i encaixa em 90% dos usuários com apenas dois tamanhos
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 19:55
Riassunto: ResMed presenta AirFit P30i, la prima maschera CPAP con cuscinetti nasali con collegamento sopra la testa
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) ha presentato oggi, AirFit P30i, la sua seconda maschera per ventilazione meccanica a pressione positiva (continuous positive airway pressure, CPAP) con collegamento sopra la testa per il trattamento delle apnee del sonno, nella nuova versione con cuscinetti nasali. Il collegamento con "tubo verso l'alto", già presente nella maschera nasale AirFit N30i di ResMed lanciata a gennaio, consente di tenere il tubo in una posizione tale da perme
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 18:41
Samenvatting: ResMed introduceert AirFit P30i, de eerste Top-of-Head-Connected Nasal Pillows CPAP Mask
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) introduceerde vandaag zijn tweede top-of-head-verbonden CPAP-masker voor de behandeling van slaapapneu, een nieuwe neuskussenoptie, AirFit P30i. De "tube-up" verbinding van het masker, die ook te vinden is op ResMed's AirFit N30i neusmasker dat in januari op de markt is gebracht, zorgt ervoor dat de slangen van het masker uit de buurt blijven van de drager, zodat ze in elke positie kunnen bewegen en slapen. Deze bekendmaking is officieel
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 18:41
ResMed introduce AirFit P30i, su primera máscara CPAP de almohadillas nasales conectadas por encima de la cabeza
SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) introdujo hoy AirFit P30i, su segunda máscara CPAP conectada por encima de la cabeza para tratar la apnea del sueño, una nueva opción de almohadillas nasales. La conexión "sonda arriba" de la máscara, que también se presenta en la máscara nasal AirFit N30i, de ResMed, lanzada en enero, mantiene la sonda apartada del usuario para que el mismo pueda moverse y dormir en cualquier posición. AirFit P30i es apta para el 90 por ciento de los usu
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 18:41
Axcella Presents Late-Breaker Data Demonstrating Lead AXA™ Candidate AXA1665 Impacted Markers Related to Liver Health
CAMBRIDGE, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/AXAcandidates?src=hash" target="_blank"gt;#AXAcandidateslt;/agt;--Axcella Presents Late-Breaker Data Demonstrating Lead AXA™ Candidate AXA1665 Impacted Markers Related to Liver Health
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 18:00
Study Published in Antimicrobial Agents and Chemotherapy Finds Antifungal Compound VT-1598 Developed by Mycovia Pharmaceuticals Demonstrates In Vitro and In Vivo Activity Against Deadly Candida Auris Fungus
DURHAM, N.C.--(BUSINESS WIRE)--Published Study Finds Mycovia's Antifungal Compound VT-1598 Demonstrates In Vitro and In Vivo Activity Against Deadly Candida Auris Fungus
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 17:21
Enanta Pharmaceuticals Presents New Preclinical Data on Compounds Targeting Hepatitis B Virus and Non-Alcoholic Steatohepatitis at The International Liver Congress™ 2019
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that new preclinical data from Enanta's wholly-owned development programs for hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH) will be presented at The International Liver Congress™ (ILC) 2019, in Vienna, Austria. New data include a presentation on deve
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 17:13
Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data on the use of its chronic hepatitis B (HBV) and hepatitis C (HCV) medicines including safety and efficacy data on Vemlidy® (tenofovir alafenamide 25mg, TAF) in HBV patients previously treated with tenofovir disoproxil fumarate (TDF) and data on Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in difficult-to-cure HCV patient populations. These results,
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 16:18
AriBio Co., Ltd. Announces First Patient Dosing in Phase 2 Study of AR1001 for Alzheimer's Disease
SAN DIEGO--(BUSINESS WIRE)--AriBio Co., Ltd. just announced the first patient dosing in their Phase 2 study for Alzheimer's disease.
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 16:00
Sensei Biotherapeutics Announces Formation of New Immuno-Oncology Advisory Board
GAITHERSBURG, Md.--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the formation of a new Immuno-Oncology Advisory Board (IOAB), consisting of several world-recognized and credentialed experts in the fields of immuno-oncology, tumor biology, vaccinology, cell therapy, and precision medicine. The IOAB will collaborate closely with members of Sensei's management team to support the advancemen
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 15:00
GT Medical Technologies Co-Founder to Receive Prestigious Rosenblum-Mahaley Clinical Research Award at 2019 American Association of Neurological Surgeons Annual Scientific Meeting
TEMPE, Ariz. & SAN DIEGO--(BUSINESS WIRE)--GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that Peter Nakaji, M.D., GT MedTech's co-founder and director of the Neurosurgery Residency Program at Barrow Neurological Institute in Phoenix, has been selected by the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors to receive the Rosenblum-Mahaley Clinical Research Awa
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 15:00
LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma, a global leader in medical dermatology and BIOMAP, a EU-funded research project (Biomarkers in Atopic Dermatitis and Psoriasis), today announced that BIOMAP kicks off its activities with the aim of improving the lives of patients affected by the two most common inflammatory skin conditions. Addressing key unmet needs in treating atopic dermatitis and psoriasis by analysing data from more than 50,000 patients, the five-year project will have a broa
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 14:51
Newly Published Independent, Prospective Study Reinforces Prognostic Accuracy of DecisionDx-Melanoma in Cutaneous Melanoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced publication of an independent, prospective study of 159 patients with cutaneous melanoma showing that the DecisionDx®-Melanoma gene expression profile (GEP) test accurately identified risk of melanoma recurrence independent of other prognostic factors such as Breslow thickness and sentinel lymph node b
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 14:00
ResMed Introduces AirFit P30i, Its First Top-of-Head-Connected Nasal Pillows CPAP Mask
SAN DIEGO--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24RMD&src=ctag" target="_blank"gt;$RMDlt;/agt; lt;a href="https://twitter.com/hashtag/CPAP?src=hash" target="_blank"gt;#CPAPlt;/agt;--ResMed now offers "tube-up" CPAP masks for nasal and nasal pillows wearers: the AirFit P30i and AirFit N30i.
Business Wire Health: Clinical Trials News
Thu Apr 11, 2019 10:00

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις